Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4 (2017)
- Authors:
- Autor USP: HEGG, ROBERTO - FM
- Unidade: FM
- Subjects: NEOPLASIAS MAMÁRIAS; PROGNÓSTICO; SOBREVIVÊNCIA LIVRE DE DOENÇA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Annals of oncology
- ISSN: 0923-7534
- Volume/Número/Paginação/Ano: v. 28, suppl.5, 2017
- Conference titles: 42nd European-Society-for-Medical-Oncology Congress (ESMO)
-
ABNT
BACHELOT, T; ROYCE, M; VILLANUEVA, C; et al. Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4. Annals of oncology[S.l: s.n.], 2017. -
APA
Bachelot, T., Royce, M., Villanueva, C., Cruz, F. M., Hegg, R., Falkson, C., et al. (2017). Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4. Annals of oncology. Oxford. -
NLM
Bachelot T, Royce M, Villanueva C, Cruz FM, Hegg R, Falkson C, Jeong J, Srimuninnimit V, Arce CH, Ridolfi A. Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4. Annals of oncology. 2017 ; 28 -
Vancouver
Bachelot T, Royce M, Villanueva C, Cruz FM, Hegg R, Falkson C, Jeong J, Srimuninnimit V, Arce CH, Ridolfi A. Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4. Annals of oncology. 2017 ; 28 - Recursos terapêuticos na doente terminal
- Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
- Câncer de mama
- Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial
- Como diagnosticar e tratar sindrome do climaterio
- Galactorreia: sindrome hiperprolactinemica
- Hormonioterapia de reposicao e cancer de mama
- Prevencao da osteoporose
- Mastite puerperal
- Evaluation the predictive value of biomarkers for efficacy outcomes in response to pertuzumab and trastuzumab based therapy: An exploratory analysis of the tryphaena study
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
